The company said full-year fiscal 2024 total revenue rose 12% to $5.5 billion, with U.S. GAAP diluted earnings per share of $3.81 and adjusted diluted earnings per share of $8.83.

1. 01

   The company said full-year fiscal 2024 total revenue rose 12% to $5.5 billion, with U.S. GAAP diluted earnings per share of $3.81 and adjusted diluted earnings per share of $8.83.

2. 02

   The company said it reported a U.S. GAAP net loss of $1.4 million ($0.01 per diluted share) for the fiscal 2024 Q4, which was affected by a pre-tax loss of $206.4 million recognized upon reclassifying the Dental segment as discontinued operations.

3. 03

   The company said it recorded $44.4 million of the approximately $100 million in targeted restructuring charges in the fiscal 2024 Q4 and expects the balance to be recorded in fiscal 2025. It said approximately $50 million of the charges are non-cash.

4. 04

   The company said it expects adjusted diluted earnings per share from continuing operations for fiscal 2025 to be in the range of $9.05 to $9.25 and free cash flow of about $700 million. Free cash flow for fiscal 2024 was $620.3 million.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.